Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) is now available.
Jubilant Pharmova has disclosed that its wholly owned subsidiary, Jubilant Biosys Limited, has received an order from the Joint Commissioner of GST in Noida confirming a Goods and Services Tax demand of Rs 6.98 crore and a penalty of Rs 2.72 crore for the financial years 2020-21 to 2022-23, arising from alleged discrepancies in input tax credit claims. The company contends that the demand is legally untenable and based on frivolous grounds despite prior submission of documents, and it plans to challenge the order before the Commissioner (Appeals); management maintains that the case has strong merits, and asserts there will be no material impact on the group’s financials, operations or other activities, suggesting limited immediate risk for shareholders and other stakeholders.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited operates in the pharmaceuticals and life sciences industry, with activities spanning drug discovery, development and manufacturing through its subsidiaries such as Jubilant Biosys Limited. The group focuses on providing contract research and related services to global pharmaceutical and biotech companies, positioning itself as a key player in India’s broader pharma and contract research ecosystem.
Average Trading Volume: 7,470
Technical Sentiment Signal: Buy
Current Market Cap: 172B INR
Find detailed analytics on JUBLPHARMA stock on TipRanks’ Stock Analysis page.